PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
US11780923B2 · kind B2 · utility
0Cited by
5References
23Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 7, 2020 |
| Grant date | Oct 10, 2023 |
| Priority date | — |
| Expiry date | Jan 2, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.